As a product of glycolysis and the starting substrate of the Kreb's cycle, pyruvate plays a key role in intermediary metabolism. It is also an important endogenous scavenger of ROS such as H
2O
2, OH
. , and peroxynitrite. Therefore, pyruvate has been studied extensively as a protective agent for cellular systems exposed to oxidative stress conditions in a variety of in vitro and in vivo models of diverse pathologic conditions.
4 However, the use of pyruvate as a potential therapeutic agent is limited because of its poor stability in aqueous solutions. Therefore, a closely related and more aqueous stable form of pyruvate is warranted. Recently, an ester form of pyruvate (EP) believed to be more stable than an anionic form has been developed. Several studies revealed that EP is more effective in ameliorating oxidative stress-induced injuries or tissue alterations than pyruvate itself.
14,15,33 Moreover, four crucial findings by Ulloa et al.
7 have established EP as an excellent anti-inflammatory agent. These are: (1) EP inhibits the LPS-induced secretion of the proinflammatory TNF-α in a concentration-dependent fashion. (2) Treatment with EP improves survival in mice challenged with a lethal dose of LPS or rendered septic by cecal ligation and perforation (CLP). Importantly, the therapeutic benefit of EP is evident in the CLP model of polymicrobial sepsis even though it injected 24 hours after the onset of infection. (3) EP inhibits secretion of the proinflammatory DNA-binding protein, high mobility group box 1 (HMGB1) in vitro and in vivo conditions. (4) EP attenuates the activation of two key proinflammatory signaling pathways, NF-κB and p38 mitogen-activated protein kinase (MAPK). These earlier findings by Ulloa et al.
7 have been confirmed and extended by numerous follow-up studies.
8 –13,34 However, the therapeutic efficacy of EP in ocular diseases has not been explored extensively. Recently, few studies reported that EP could prevent corneal wound healing,
35 oxidative damage to lens and sugar and galactose cataracts in rodents.
14 –16,36 Moreover, in rats, the instillation of 5% EP (50 g/L or 430 mM) is well tolerated over a 40-day experimental period, and penetration of EP through the cornea is rapid, with pyruvate concentration in the AqH reaching 7 mM after 15 minutes.
16 Similarly, topical administration of EP in mouse eyes caused an increase in the levels of pyruvate in the AqH and in the lens, the peak concentrations being 4.7 and 3.6 mM, respectively.
37 These studies suggest that EP could also be an efficient therapeutic agent for the intervention of other inflammatory ocular conditions.